Print
Email
Print Edition StoriesWednesday, December 30, 2009
FDA rejects SPA for Vion anti-cancer drug candidate
By Mass High Tech staff
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
Robotic surgery gains traction
Funding drugs for rare diseases
Vion Pharmaceuticals Inc. has received notice from the U.S. Food and Drug Administration that its request for a special protocol assessment (SPA) of its Onrigin anti-cancer compound require enough changes to warrant a new Phase 3 clinical trial. The FDA cited concerns with the primary endpoint and study regimen of the trial.
The New Haven, Conn.-based oncology drug maker announced two weeks ago that it had voluntarily filed for Chapter 11 bankruptcy protection. Without completing its Phase 3 trial, Vion officials had hoped for an SPA to receive FDA approval for the acute myeloid leukemia-focused drug candidate. Vion conducted a randomized trial, sponsored by the Dutch-Belgian Cooperative Group for Hematology Oncology (HOVON), following the FDA’s request after the company submitted a new drug application for Onrigin.
Vion now has two weeks to decide whether it will file another SPA for an “alternative randomized Phase 3 trial.”
Vion’s Onrigin was intended to be a single agent for remission treatment for patients 60 years old or older with de novo poor-risk acute myeloid leukemia.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
